tradmap

RGNX Regenxbio Inc.

$9.19 -4.27%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Regenxbio Inc. (RGNX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $607 million. Shares last traded at $9.19, 43.2% below their 52-week high. Over the past year the stock is down 6.9%. Net profit margin is -112.6%, below the peer median of 5.3%. Revenue grew 104.5% year over year.

Market Cap
$607M
Shares Out
66.0M
EPS (TTM)
$-6.72
P/E Ratio
P/S Ratio
3.48
P/B Ratio
8.45
Dividend / Share
Dividend Yield
52-Week High
$16.19
52-Week Low
$5.46
Volume
41,438
Avg Vol (3m)
97,838.429

Performance

1W
-7.17%
1M
-12.31%
3M
+33.67%
6M
+5.51%
YTD
-32.28%
1Y
-6.89%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
43.24
SMA (50)
$10.99
SMA (200)
$10.34
Price vs SMA50
-16.35%
Price vs SMA200
-11.16%
ATR (14)
$0.98

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$174M
Net Income
$-196M
Gross Margin
Operating Margin
-94.1%
Net Margin
-112.6%
Return on Equity
-273.7%
Return on Assets
-50.8%
Current Ratio
2.86
Debt / Equity
4.39
Revenue Growth (YoY)
+104.5%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-1.28 2026-08-06
Q1 2026 $-1.72 2026-05-14
FY 2025 $-3.76 2026-03-05
Q3 2025 $-2.46 2025-11-06
Q2 2026 $-1.26 2026-08-06
Q1 2026 $0.12 2026-05-14

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

RGNX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
3.48 / 19.49 med
-82% discount
Net margin vs peers
-112.6% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.